| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Gain on long-term investment | - | 3,390 | ||
| Total other income and expense | 1,365 | 4,585 | ||
| Loss from operations before income taxes | -20,283 | -26,103 | ||
| Net loss | -20,283 | -26,103 | ||
| Earnings per share, basic | -0.33 | -0.6 | ||
| Net loss per common share, diluted | -0.33 | -0.6 | ||
| Weighted-average common shares outstanding, basic | 60,980,867 | 43,573,628 | ||
| Weighted-average common shares outstanding, diluted | 60,980,867 | 43,573,628 | ||
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)